Home > Cardiology > ESC 2022 > ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridemia

ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridemia

Presented By
Prof. Deepak Bhatt, Harvard Medical School, Boston, MA, USA
Conference
ESC 2022
Trial
Phase 2, ENTRIGUE
In a phase 2 study, treating patients with severe hypertriglyceridaemia with subcutaneous FGF21 analogue pegozafermin significantly reduced triglycerides across all dose groups compared with placebo. Triglyceride reductions after 8 weeks of therapy showed that 75% of participants who received 27 mg of pegozafermin weekly achieved a >50% triglycerides reduction, without serious side effects. FGF21 regulates lipid and glucose metabolism, and its analogue pegozafermin extends FGF21 half-life by 25–50-fold. The dose-finding ENTRIGUE trial (NCT04541186) hypothesised that pegozafermin would give some signal of reduced triglycerides in patients with severe hypertriglyceridaemia. The initial findings were presented by Prof. Deepak Bhatt (Harvard Medical School, Boston, MA, USA) [1]. ENTRIGUE was a randomised, double-blind, phase 2 trial of patients (n=85, average age 54...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on